Influenza News and Research

Latest Influenza News and Research

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

Researchers find influenza vaccines can contain allergenic components

People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.

15 Nov 2010

Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.

12 Nov 2010

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona. The presentation was entitled DAS181 (Fludase), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling.

12 Nov 2010

Meridian fourth quarter net sales decrease 16% to $35.5 million

Meridian Bioscience, Inc., reported fourth quarter and full-year fiscal 2010 net sales of $35.5 million and $143.0 million, respectively, decreases of 16% and 4%, respectively, from the same periods of the prior fiscal year.

11 Nov 2010

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.

11 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Flu vaccination programs can protect employee health, save businesses money

Each year, influenza poses a tremendous burden on working adults and the many businesses that employ them, contributing to absenteeism and lost productivity. Yet, annual influenza immunization rates remain very low. New data out today show that employer-sponsored influenza vaccination programs held early in the flu season not only protect employee health, but save businesses money.

10 Nov 2010

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Acute respiratory infections (ARIs) - such as influenza, pneumonia and respiratory syncytial virus (RSV) - cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).

10 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Vaccinations do not increase risk of RA

Common adult vaccinations are not associated with an increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74th ACR Scientific Meeting being held in Atlanta, Georgia.

9 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Experts develop tools to educate people about health risks associated with global travel

More than 30 million people in the United States travel to resource-limited areas of the world each year. This global mobility may contribute to the spread of infectious diseases such as influenza, measles, and meningitis and may also put individual travelers at risk for malaria, typhoid, dengue fever and hepatitis.

4 Nov 2010

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Idaho Technology, Inc. (ITI) announced today that it has filed a submission with the U.S. Food and Drug Administration for 510(k) clearance to market its FilmArray Respiratory Panel (RP) as an in vitro diagnostic product for patients with symptoms of upper respiratory tract infection.

4 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010